Unlock instant, AI-driven research and patent intelligence for your innovation.

Purified mammalian CTLA-8 antigens and related reagents

a technology of ctla-8 and antigens, which is applied in the field of purified mammalian ctla-8 antigens and related reagents, can solve the problems of preventing the ability to advantageously modulate the normal defense mechanism to biological challenges, affecting the ability of cells to express different developmental stages of cells in different developmental stages, and incompletely identifying the roles and mechanisms of action of signaling molecules in influencing, supporting, or modulating the various physiological, developmental or pro

Inactive Publication Date: 2005-12-01
SCHERING CORP
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] The invention includes an antibody which specifically binds to a primate CTLA-8 protein or peptide thereof; the antibody is raised against a protein sequence of SEQ ID NO: 2, 4, 6, 8 or 10; the antibody is a monoclonal antibody; the antibody blocks the CTLA-8 induced secretion of an inflammatory mediator, e.g., IL-6, IL-8, and/or PGE2; or the

Problems solved by technology

However, the cellular molecules which are expressed by different developmental stages of cells in these maturation pathways are still incompletely identified.
Moreover, the roles and mechanisms of action of signaling molecules which induce, sustain, or modulate the various physiological, developmental, or proliferative states of these cells is poorly understood.
However, the lack of understanding of how the immune system is regulated or differentiates has blocked the ability to advantageously modulate the normal defensive mechanisms to biological challenges.
Medical conditions characterized by abnormal or inappropriate regulation of the development or physiology of relevant cells thus remain unmanageable.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

examples

I. General Methods

[0165] Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual, (2d ed.), vols. 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, N.Y.; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology, Greene / Wiley, N.Y.; Innis, et al. (eds.)(1990) PCR Protocols: A Guide to Methods and Applications Academic Press, N.Y. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) “Guide to Protein Purification” in Methods in Enzymology, vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purifica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Login to View More

Abstract

CTLA-8 antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.

Description

[0001] The present application is a continuation-in-part of copending U.S. Ser. No. 08 / 250,846, filed May 27, 1994, which is a continuation-in-part of then copending patent application U.S. Ser. No. 08 / 177,747, filed Jan. 5, 1994, which is a continuation-in-part of then copending patent application U.S. Ser. No. 08 / 077,203, filed Jun. 14, 1993, each of which is incorporated herein by reference. Also incorporated by reference is co-pending PCT / US95 / 00001, filed Jan. 3, 1995.FIELD OF THE INVENTION [0002] The present invention relates to compositions related to proteins which function in controlling physiology, development, and differentiation of mammalian cells, e.g., cells of a mammalian immune system. In particular, it provides proteins and mimetics which regulate cellular physiology, development, differentiation, or function of various cell types, including hematopoietic cells. BACKGROUND OF THE INVENTION [0003] The immune system of vertebrates consists of a number of organs and se...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/00C07H21/04C07K14/52C07K14/715C07K16/24C07K16/30C12N5/06C12N15/09C12P21/06C12Q1/68
CPCA61K38/00C07K14/52Y10S435/975C07K16/244C07K14/715
Inventor GOLSTEIN, PIERREROUVIER, ERICFOSSIEZ, FRANCOISLEBECQUE, SERGEDJOSSOU, ODILEBANCHEREAU, JACQUES
Owner SCHERING CORP